Ignite Creation Date:
2025-12-24 @ 7:00 PM
Ignite Modification Date:
2025-12-29 @ 6:17 AM
Study NCT ID:
NCT03541057
Status:
RECRUITING
Last Update Posted:
2024-01-03
First Post:
2018-05-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Vienna Vascular Liver Disease Study
Sponsor:
Medical University of Vienna
Organization:
Study Overview
Official Title:
Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VALID
Brief Summary:
The aim of this Register Trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases. Furthermore, important clinical parameters will be assessed in order to evaluate patients' coagulation status and in order to develop new biomarkers derived from blood, urine, stool or ascites of patients as well as histological samples from the upper / lower GI-tract or the liver in order to better understand the natural history of vascular liver diseases.
Detailed Description:
We will include patients with vascular liver diseases, including
* portal vein thrombosis (PVT)
* Budd-Chiari Syndrome (BCS)
* Heredetary Hemorrhagic Teleangiectasia (HHT, or Osler-Rendu Disease)
* Noncirrhotic-portal hypertension (NCPH) and Porto-sinusoidal vascular disorder
* Cirrhosis cardiaque if the fulfill inclusion/exclusion criteria and provide written informed consent. Participation in the biobank is optional for the patients. In particular, we will study the natural course of the patients in regard to hepatic decompensation (ascites, variceal bleeding, hepatic encephalopathy), need for intensified treatment (TIPS, ICU, liver transplantation) and survival.
* portal vein thrombosis (PVT)
* Budd-Chiari Syndrome (BCS)
* Heredetary Hemorrhagic Teleangiectasia (HHT, or Osler-Rendu Disease)
* Noncirrhotic-portal hypertension (NCPH) and Porto-sinusoidal vascular disorder
* Cirrhosis cardiaque if the fulfill inclusion/exclusion criteria and provide written informed consent. Participation in the biobank is optional for the patients. In particular, we will study the natural course of the patients in regard to hepatic decompensation (ascites, variceal bleeding, hepatic encephalopathy), need for intensified treatment (TIPS, ICU, liver transplantation) and survival.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: